Efficacy and Safety of Flibanserin in Women with Hypoactive Sexual Desire Disorder: A Systematic Review and Meta-Analysis
- PMID: 26745616
- DOI: 10.1111/jsm.13037
Efficacy and Safety of Flibanserin in Women with Hypoactive Sexual Desire Disorder: A Systematic Review and Meta-Analysis
Abstract
Introduction: Flibanserin, is a postsynaptic agonist of serotonin receptor 1A and an antagonist of serotonin receptor 2A, has been shown to increase sexual desire and reduce distress in women with hypoactive sexual desire disorder (HSDD).
Aim: We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug in women with HSDD.
Methods: A literature review was performed to identify all published randomized double-blind, placebo-controlled trials of flibanserin for the treatment of HSDD. The search included the following databases: MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated.
Main outcome measures: Four publications involving a total of 3,414 patients were used in the analysis, including four randomized controlled trials that compared flibanserin with placebo.
Results: For the comparison of flibanserin with placebo, primary efficacy endpoints: satisfying sexual events (the standardized mean difference [SMD] = 0.59, 95% confidence interval [CI] = 0.37-0.80, P < 0.00001); sexual desire score (the SMD = 1.91, 95% CI = 0.21 to 3.60, P = 0.03) and Female Sexual Function Index (FSFI) desire domain score (the SMD = 0.32, 95% CI = 0.19-0.46, P < 0.00001) and key secondary efficacy endpoints: FSFI total score, Female Sexual Distress Scale-Revised (FSDS-R) total score, FSDS-R Item 13 score, Patient's Global Impression of Improvement score and Patient Benefit Evaluation indicated that flibanserin was more effective than the placebo. Safety assessments included the proportion of women who experienced an adverse event (odds ratio = 1.54, 95% CI = .34 to 1.76, P < 0.00001), nervous system disorders and fatigue indicated that flibanserin was well tolerated.
Conclusions: This meta-analysis indicates that flibanserin to be an effective and safe treatment for HSDD in women.
Keywords: Flibanserin; Hypoactive Sexual Desire Disorder; Meta-Analysis; Randomized Controlled Trial.
© 2015 International Society for Sexual Medicine.
Similar articles
-
Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial.J Sex Med. 2013 Jul;10(7):1807-15. doi: 10.1111/jsm.12189. Epub 2013 May 14. J Sex Med. 2013. PMID: 23672269 Clinical Trial.
-
Continued efficacy and safety of flibanserin in premenopausal women with Hypoactive Sexual Desire Disorder (HSDD): results from a randomized withdrawal trial.J Sex Med. 2011 Nov;8(11):3160-72. doi: 10.1111/j.1743-6109.2011.02458.x. Epub 2011 Sep 20. J Sex Med. 2011. PMID: 21933348 Clinical Trial.
-
Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study.J Sex Med. 2012 Apr;9(4):1074-85. doi: 10.1111/j.1743-6109.2011.02626.x. Epub 2012 Jan 16. J Sex Med. 2012. PMID: 22248038 Clinical Trial.
-
Flibanserin Efficacy and Safety in Premenopausal Women With Generalized Acquired Hypoactive Sexual Desire Disorder.Sex Med Rev. 2017 Oct;5(4):445-460. doi: 10.1016/j.sxmr.2017.05.003. Epub 2017 Jun 27. Sex Med Rev. 2017. PMID: 28666836 Review.
-
Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-analysis.JAMA Intern Med. 2016 Apr;176(4):453-62. doi: 10.1001/jamainternmed.2015.8565. JAMA Intern Med. 2016. PMID: 26927498 Review.
Cited by
-
Melanocortin 4 receptor signaling in Sim1 neurons permits sexual receptivity in female mice.Front Endocrinol (Lausanne). 2023 Mar 24;14:983670. doi: 10.3389/fendo.2023.983670. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37033219 Free PMC article.
-
Commentary on Simon et al.Sex Med. 2022 Dec;10(6):100586. doi: 10.1016/j.esxm.2022.100586. Sex Med. 2022. PMID: 36529478 Free PMC article. No abstract available.
-
Psychological Treatment of Low Sexual Desire in Women: Protocol for a Randomized, Waitlist-Controlled Trial of Internet-Based Cognitive Behavioral and Mindfulness-Based Treatments.JMIR Res Protoc. 2020 Sep 29;9(9):e20326. doi: 10.2196/20326. JMIR Res Protoc. 2020. PMID: 32990248 Free PMC article.
-
Psychosexual Functioning of Female Childhood Cancer Survivors: A Report From the St. Jude Lifetime Cohort Study.J Sex Med. 2020 Oct;17(10):1981-1994. doi: 10.1016/j.jsxm.2020.06.005. Epub 2020 Jul 25. J Sex Med. 2020. PMID: 32723681 Free PMC article.
-
Knowledge Gaps in Urologic Care of Female Spinal Cord Injury Patients.Curr Urol Rep. 2019 Mar 23;20(5):21. doi: 10.1007/s11934-019-0884-6. Curr Urol Rep. 2019. PMID: 30904966 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical